On-line adaptive MR guided radiotherapy for locally advanced pancreatic cancer: Clinical and dosimetric considerations.

Locally advanced pancreatic cancer Magnetic resonance guided radiation therapy Online adaptive radiotherapy

Journal

Technical innovations & patient support in radiation oncology
ISSN: 2405-6324
Titre abrégé: Tech Innov Patient Support Radiat Oncol
Pays: England
ID NLM: 101762366

Informations de publication

Date de publication:
Sep 2020
Historique:
received: 06 03 2020
revised: 04 06 2020
accepted: 05 06 2020
entrez: 10 7 2020
pubmed: 10 7 2020
medline: 10 7 2020
Statut: epublish

Résumé

Magnetic Resonance-guided Radiation Therapy (MRgRT) allows online adaptations (OA) of the treatment plan to optimize daily dose distribution based on patient's anatomy, just before fraction delivery. The aim of this study is to evaluate feasibility and the dosimetric improvement of the OA workflow implemented in our institution for locally advanced pancreatic cancer (LAPC) patients, in terms of target coverage and organs at risk (OARs) sparing. We retrospectively analysed 8 LAPC patients treated with MRgRT in combination with the OA approach, using video-assisted inspiratory breath-hold for a total of 38 fractions with a dose ranging from 30 Gy to 40 Gy in 5 fractions.Dose distribution of the baseline plan was first calculated based on daily anatomy, obtaining a "predicted" plan to assess the dosimetric improvement. If the dose distribution did not meet the constraints set in the planning phase, PTV, GTV and OARs were re-contoured within a distance of 3 cm from the PTV external edge and a new online "adaptive" plan was generated. Other clinical and planning parameters were also evaluated to assess the feasibility and the dosimetic benefit of the online adaptive workflow. Out of 38 total fractions, 26 (68.4%) were adapted online and 12 (31.6%) were delivered using the baseline plan. The use of the adaptive workflow resulted to be feasible in our clinical practice and advantageous in all the patients: mean PTV V95% increased by 10.8% (5.7-20.8) while mean CTV V98% of 12.6% (7.3-17.7). Also OARs V33 and V25 showed a positive trend avoiding unnecessary irradiation. OA workflow improves the dosimetric benefit of MRgRT, preventing the occurrence of high-doses to OARs and increasing the safety of stereotactic treatment for LAPC, without any drawback for our daily clinical practice routine.

Identifiants

pubmed: 32642565
doi: 10.1016/j.tipsro.2020.06.001
pii: S2405-6324(20)30015-9
pmc: PMC7334416
doi:

Types de publication

Journal Article

Langues

eng

Pagination

15-21

Informations de copyright

© 2020 The Author(s).

Déclaration de conflit d'intérêts

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Références

Cancer Med. 2019 May;8(5):2123-2132
pubmed: 30932367
Int J Radiat Oncol Biol Phys. 2010 Nov 1;78(3):735-42
pubmed: 20171803
Int J Radiat Oncol Biol Phys. 2016 Oct 1;96(2):296-303
pubmed: 27475674
Front Radiat Ther Oncol. 2007;40:386-394
pubmed: 17641521
Cancer. 2017 Sep 15;123(18):3486-3493
pubmed: 28493288
Cancer. 2009 Feb 1;115(3):665-72
pubmed: 19117351
Phys Med Biol. 2013 Jun 21;58(12):4157-74
pubmed: 23689060
Semin Radiat Oncol. 2014 Jul;24(3):196-9
pubmed: 24931092
Med Phys. 2010 Aug;37(8):4078-101
pubmed: 20879569
Phys Med. 2017 Aug;40:11-16
pubmed: 28760506
Radiol Med. 2019 Feb;124(2):145-153
pubmed: 30374650
Int J Radiat Oncol Biol Phys. 2004 Mar 15;58(4):1017-21
pubmed: 15001240
Tech Innov Patient Support Radiat Oncol. 2018 Mar 31;6:5-10
pubmed: 32095572
Radiother Oncol. 2017 Dec;125(3):439-444
pubmed: 28811038
J Clin Oncol. 2005 Jul 10;23(20):4538-44
pubmed: 16002845
Int J Radiat Oncol Biol Phys. 2012 Dec 1;84(5):1166-71
pubmed: 22543215
JAMA. 2016 May 3;315(17):1844-53
pubmed: 27139057
Semin Radiat Oncol. 2016 Apr;26(2):149-56
pubmed: 27000512
Cancer. 2000 Dec 1;89(11):2222-9
pubmed: 11147592
Radiat Oncol. 2019 Apr 29;14(1):71
pubmed: 31036034
Ann Surg. 2017 Aug;266(2):333-338
pubmed: 27429020
Int J Radiat Oncol Biol Phys. 2010 Dec 1;78(5):1420-6
pubmed: 20399033
Cancer J. 2011 May-Jun;17(3):182-9
pubmed: 21610472
Int J Radiat Oncol Biol Phys. 2008 Nov 1;72(3):678-86
pubmed: 18395362
Z Med Phys. 2018 Aug;28(3):173-174
pubmed: 29602589
Radiat Oncol. 2012 May 18;7:74
pubmed: 22607687
Int J Radiat Oncol Biol Phys. 2011 Nov 15;81(4):e615-22
pubmed: 21658854
Ann Surg Oncol. 2009 Jul;16(7):1727-33
pubmed: 19396496
J Oncol Pract. 2017 Mar;13(3):157-166
pubmed: 28282277

Auteurs

Lorenzo Placidi (L)

Università Cattolica del Sacro Cuore, Largo Agostino Gemelli 8, 00168 Rome, Italy.
Fondazione Policlinico Universitario Agostino Gemelli IRCCS , Largo Francesco Vito 1, 00168 Rome, Italy.

Angela Romano (A)

Fondazione Policlinico Universitario Agostino Gemelli IRCCS , Largo Francesco Vito 1, 00168 Rome, Italy.

Giuditta Chiloiro (G)

Fondazione Policlinico Universitario Agostino Gemelli IRCCS , Largo Francesco Vito 1, 00168 Rome, Italy.

Davide Cusumano (D)

Fondazione Policlinico Universitario Agostino Gemelli IRCCS , Largo Francesco Vito 1, 00168 Rome, Italy.

Luca Boldrini (L)

Università Cattolica del Sacro Cuore, Largo Agostino Gemelli 8, 00168 Rome, Italy.
Fondazione Policlinico Universitario Agostino Gemelli IRCCS , Largo Francesco Vito 1, 00168 Rome, Italy.

Francesco Cellini (F)

Fondazione Policlinico Universitario Agostino Gemelli IRCCS , Largo Francesco Vito 1, 00168 Rome, Italy.

Gian Carlo Mattiucci (GC)

Università Cattolica del Sacro Cuore, Largo Agostino Gemelli 8, 00168 Rome, Italy.
Fondazione Policlinico Universitario Agostino Gemelli IRCCS , Largo Francesco Vito 1, 00168 Rome, Italy.

Vincenzo Valentini (V)

Università Cattolica del Sacro Cuore, Largo Agostino Gemelli 8, 00168 Rome, Italy.
Fondazione Policlinico Universitario Agostino Gemelli IRCCS , Largo Francesco Vito 1, 00168 Rome, Italy.

Classifications MeSH